{
    "clinical_study": {
        "@rank": "95853", 
        "arm_group": [
            {
                "arm_group_label": "INCT", 
                "arm_group_type": "Experimental", 
                "description": "Arm 1 will receive chemotherapy before chemoradiation. This is called induction neoadjuvant chemotherapy arm (INCT). The neoadjuvant chemotherapy regimen is prescribed specifically as 8 cycles of FOLFOX or 6 cycles of CapeOX over a period of approximately 16-18 weeks. Endoscopic exam (2-4 wks) after chemotherapy. If stable or response then pt will have radiation with either 5-FU or capecitabine."
            }, 
            {
                "arm_group_label": "CNCT", 
                "arm_group_type": "Experimental", 
                "description": "Arm 2 will receive chemoradiation before chemotherapy This is called the consolidation neoadjuvant chemotherapy arm (CNCT). Pt will have 6 weeks of chemoradiation therapy. Along with the radiation the pt will receive either 5-FU or capecitabine. 2-4 weeks after pt will have endoscopic exam and if stable or response pt will have will have 8 cycles of FOLFOX or 6 cycles of CapeOX."
            }
        ], 
        "brief_summary": {
            "textblock": "The study is designed to test the hypothesis that patients with distal Locally advanced\n      rectal cancer ( LARC) treated with  Total neoadjuvant therapy (TNT) and Total mesorectal\n      excision (TME) or  Non-operative management (NOM) will have an improved 3-year disease-free\n      survival (DFS) compared to patients with similar tumors treated with Chemoradiation therapy\n      (CRT),  Total mesorectal excision (TME) and Adjuvant chemotherapy (ACT)."
        }, 
        "brief_title": "Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management", 
        "condition": "Rectal Cancer", 
        "condition_browse": {
            "mesh_term": "Rectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed diagnosis of adenocarcinoma of the rectum Clinical Stage II\n             (T3-4, N0) or Stage III (any T, N1-2)\n\n          -  Distal tumor margin at \u2264 6 cm from the anal verge or patients who require an APR or\n             CAA according to treating physician\n\n          -  No evidence of distant metastases\n\n          -  No prior pelvic radiation therapy\n\n          -  No prior chemotherapy or surgery for rectal cancer\n\n          -  Age > or = 18 years\n\n          -  No infections requiring systemic antibiotic treatment\n\n          -  ECOG Performance status 0-2\n\n          -  Women with childbearing potential (WOCBP) who are negative for pregnancy test (urine\n             or blood) and who agree to use effective contraceptive method. A woman of\n             childbearing potential is defined of one who is biologically capable of becoming\n             pregnant. Reliable contraception should be used from trial screening and must be\n             continued throughout the study.\n\n          -  Patients must read, agree to, and sign a statement of Informed Consent prior to\n             participation in this study. Patients who do not read or understand English are\n             eligible and may be consented according to institutional and federal regulations.\n\n          -  ANC > 1.5 cells/mm3, HGB > 8.0 gm/dl, PLT > 150,000/mm3  total bilirubin \u2264 1.5 x ULN,\n             AST\u2264 3 x ULN, ALT \u2264 3 x ULN.\n\n        Exclusion Criteria:\n\n          -  Recurrent rectal cancer\n\n          -  Primary unresectable rectal cancer. A tumor is considered unresectable when invading\n             adjacent organs and an en block resection will not achieve negative margins.\n\n          -  Serum creatinine level greater than 1.5 times the upper limit of normal.\n\n          -  Patients who have received prior pelvic radiotherapy.\n\n          -  Patients with a history of any arterial thrombotic event within the past 6 months.\n             This includes angina (stable or unstable), MI, TIA, or CVA.\n\n          -  Patients with a history of venous thrombotic episodes such as deep venous thrombosis,\n             pulmonary embolus occurring more than 6 months prior to enrollment may be considered\n             for protocol participation, provided they are on stable doses of anticoagulant\n             therapy. Similarly, patients who are anticoagulated for atrial fibrillation or other\n             conditions may participate, provided they are on stable doses of anticoagulant\n             therapy.\n\n          -  Other Anticancer or Experimental Therapy. No other experimental therapies (including\n             chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene\n             therapy, vaccine therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors,\n             thalidomide, anti-VEGF/Flk-1 monoclonal antibody or other experimental drugs) of any\n             kind are permitted while the patient is receiving study treatment.\n\n          -  WOCBP who are unwilling or unable to use an acceptable method of avoiding pregnancy\n             for the entire study period.\n\n          -  Women who are pregnant or breast-feeding.\n\n          -  Patients with any other concurrent medical or psychiatric condition or disease which,\n             in the investigator's judgment, would make them inappropriate candidates for entry\n             into this study.\n\n          -  Patients with a history of a prior malignancy within the past 5 years, except for\n             adequately treated basal cell or squamous cell skin cancer or in situ cervical\n             cancer."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "222", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02008656", 
            "org_study_id": "13-213"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "INCT", 
                    "CNCT"
                ], 
                "intervention_name": "Oxaliplatin (OXAL)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "INCT", 
                    "CNCT"
                ], 
                "intervention_name": "5-Fluorouracil (5-FU)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "INCT", 
                    "CNCT"
                ], 
                "intervention_name": "Leucovorin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "INCT", 
                    "CNCT"
                ], 
                "intervention_name": "Capecitabine (Xeloda\u00ae)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "INCT", 
                    "CNCT"
                ], 
                "intervention_name": "intensity modulated radiotherapy (IMRT)", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": [
                    "INCT", 
                    "CNCT"
                ], 
                "intervention_name": "Quality of Life Questionnaires", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": [
                    "INCT", 
                    "CNCT"
                ], 
                "intervention_name": "DRE-Endoscopy", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Capecitabine", 
                "Oxaliplatin", 
                "Leucovorin", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "CAPECITABINE (ORAL)", 
            "FLUOROURACIL", 
            "LEUCOVORIN", 
            "OXALIPLATIN", 
            "Total mesorectal excision", 
            "Chemoradiation therapy", 
            "Total neoadjuvant therapy", 
            "13-213"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Julio Garcia Aguilar, MD", 
                    "phone": "212-639-5117"
                }, 
                "facility": {
                    "address": {
                        "city": "Basking Ridge", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07920"
                    }, 
                    "name": "Memorial Sloan-Kettering at Basking Ridge"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Julio Garcia Aguilar, MD", 
                    "phone": "212-639-5117"
                }, 
                "facility": {
                    "address": {
                        "city": "Commack", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11725"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center @ Suffolk"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Julio Garcia-Aguilar, MD", 
                    "phone": "212-639-5117"
                }, 
                "contact_backup": {
                    "last_name": "Leonard Saltz, MD", 
                    "phone": "646-888-4181"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Julio Garcia-Aguilar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Julio Garcia Aguilar, MD", 
                    "phone": "212-639-5117"
                }, 
                "facility": {
                    "address": {
                        "city": "Rockville Centre", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Memorial Sloan-Kettering at Mercy Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Julio Garcia Aguilar, MD", 
                    "phone": "212-639-5117"
                }, 
                "facility": {
                    "address": {
                        "city": "Sleepy Hollow", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10591"
                    }, 
                    "name": "Memoral Sloan Kettering Cancer Center at Phelps"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management", 
        "overall_contact": {
            "last_name": "Julio Garcia Aguilar, MD", 
            "phone": "212-639-5117"
        }, 
        "overall_contact_backup": {
            "last_name": "Leonard Saltz, MD", 
            "phone": "646-888-4181"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Julio Garcia Aguilar, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "3-year DFS will be defined as the percentage of patients alive without recurrence of disease at 3 years measured from the date of randomization", 
            "measure": "disease-free survival (DFS)", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02008656"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Adverse events will be graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.", 
            "measure": "major adverse events", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Colon and Rectal Surgery Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "The Cleveland Clinic", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "John Muir Health", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Oregon Health and Science University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "St. Joseph Hospital Health Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Calgary", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of California, Irvine", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of California, San Francisco", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Chicago", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of South Florida", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Vermont", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Washington", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Washington Hospital Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Washington University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}